Page 55 of 212
Splice switching an oncogenic ratio of SmgGDS isoforms as a strategy to diminish malignancy
February 29, 2020
Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
Zhou H, Meng J, Malerba A, Catapano F, Sintusek P, Jarmin S, Feng L, Lu-Nguyen N, Sun L, Mariot V, Dumonceaux J, Morgan JE, Gissen P, Dickson G, Muntoni F. J Cachexia Sarcopenia Muscle. 2020 Feb 7. PubMed
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, …
Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors
Doman JL, Raguram A, Newby GA, Liu DR. Nat Biotechnol. 2020 Feb 10. PubMed
Page 55 of 212
Page 55 of 212
Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
Zhou H, Meng J, Malerba A, Catapano F, Sintusek P, Jarmin S, Feng L, Lu-Nguyen N, Sun L, Mariot V, Dumonceaux J, Morgan JE, Gissen P, Dickson G, Muntoni F. J Cachexia Sarcopenia Muscle. 2020 Feb 7. PubMed
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, …
Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors
Doman JL, Raguram A, Newby GA, Liu DR. Nat Biotechnol. 2020 Feb 10. PubMed
Page 55 of 212
